.jpg "Jazz Pharmaceuticals (NASDAQ: JAZZ)")
In a report released today, Esther Rajavelu from Oppenheimer maintained a Buy rating on Jazz Pharmaceuticals (JAZZ), with a price target of $180. The company’s shares opened today at $128.65.
Rajavelu noted:
“We attended an analyst briefing hosted by JAZZ management and walked away excited about the upcoming catalysts in 2019. Most important, in our view, management indicated it is operating the business to drive earnings growth over time; however, it is willing to make the necessary near-term investments for longer- term value creation. To that end, it highlighted its growing pipeline and strategic investments in both the sleep and hematology franchises. We highlight a few of these below, and note 2019 could be a breakthrough year for JAZZ with potential new product launches and several clinical readouts across its pipeline (Exhibit 1).”
According to TipRanks.com, Rajavelu is a 1-star analyst with an average return of -5.2% and a 31.3% success rate. Rajavelu covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co Ltd, Aerie Pharma, and Teva Pharma.
Jazz Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $186.55, representing a 45.0% upside. In a report issued on January 4, Cantor Fitzgerald also maintained a Buy rating on the stock with a $201 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $184 and a one-year low of $113.52. Currently, Jazz Pharmaceuticals has an average volume of 734.1K.
Based on the recent corporate insider activity of 92 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of JAZZ in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Jazz Pharmaceuticals Plc operates as a specialty biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain and psychiatry.
